The tauopathies market is expected to be driven by the launch of a first-to-market drug, says a report by GlobalData.
Titled ‘PharmaFocus: Tauopathies – Global Market Analysis’, the report projects the launch of a first-to-market drug that will encourage pharmaceutical companies to focus their research and development (R&D) efforts on the market.
The tauopathies market includes more than 20 neurodegenerative diseases such as progressive supranuclear palsy and corticobasal degeneration caused by the aggregation of tau protein in the brain. No approved therapies are currently available to treat the disease.
Approval of the first drug is expected to not only secure a high patient share, but also set an effective therapeutic approach and regulatory approval process for the market.
A disease-modifying approach will extend patients’ lives and a symptomatic treatment will provide relief for patients. It will also make the market attractive for manufacturers, driving R&D investments and reducing the financial risk associated with development.
Additionally, approval of a tauopathy drug is expected to promote the off-label use for other indications further driving sales, according to GlobalData healthcare analyst Akiko Fukui, MSc. There is a strong possibility of expanding the sales of tauopathy drugs in the Alzheimer’s disease space, which can generate huge revenues for drug manufacturers.
Four products to treat tauopathies are currently in late-stage development, including Avanir / Otsuka’s AVP-786, AB Sciences’ masitinib, TauRx Pharmaceuticals’ TRx-237, and Sellas / Catalent’s zolpidem. Additionally, a number of other products are in early / pre-clinical / discovery stages.